LRRK2 and Parkinson disease: Ahamadi et al.51found that the rate of progression based on MDS‐UPDRS I was approximately 60% lower in carriers of LRRK2 gene mutations compared to noncarriers, suggesting that the progression of nonmotor symptoms in PD could be predicted by LRRK2 gene mutations.